Get startedLog in
    Picture of Novo Nordisk A/S logo

    NOVO B — Novo Nordisk A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapNeutral
    All News

    China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug

    Picture of Novo Nordisk A/S logoNovo Nordisk A/S
    29/09/2026 05:44
    China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
    Sept 29 (Reuters) - Jiangsu Hengrui Pharmaceuticals 600276.SS, China's largest drugmaker by market value, said on Tuesday it will license global rights to its weight-management drug HRS-1596 to Novo Nordisk A/S NOVOb.CO in a deal worth up to $2.6 billion.
    Under the agreement, Novo Nordisk gains exclusive rights to develop, manufacture and commercialise the drug outside certain regions, with the Danish drugmaker paying an upfront fee of $300 million.

    (Reporting by Shivangi Lahiri in Bengaluru; Editing by Harikrishnan Nair)
    ((Shivangi.Lahiri@thomsonreuters.com;))

    Recent news on Novo Nordisk A/S

    See all news